Ignite Creation Date:
2026-03-26 @ 3:20 PM
Ignite Modification Date:
2026-03-31 @ 9:09 PM
Study NCT ID:
NCT07487220
Status:
COMPLETED
Last Update Posted:
2026-03-25
First Post:
2026-03-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Non-invasive Remote Ischemic PreConditioning (RIPC) in Free Flaps for Breast Reconstruction
Sponsor:
Ruhr University of Bochum
Organization:
Study Overview
Official Title:
Non-invasive Remote Ischemic PreConditioning in Free Flaps for Breast Reconstruction
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RIPC
Brief Summary:
This prospective randomized clinical study investigates the effects of Remote Ischemic Conditioning (RIC) on tissue perfusion and ischemia-reperfusion injury in patients undergoing free flap reconstruction in reconstructive microsurgery. RIC is a non-invasive conditioning technique using cyclic ischemia and reperfusion applied to an extremity, which may enhance microcirculation and induce tissue protection.
The study aims to evaluate whether preoperative RIC improves postoperative flap perfusion, reduces ischemia-reperfusion- related tissue damage, and enhances clinical outcomes such as flap survival, wound healing, and need for revision surgery. Patients undergoing free flap procedures will be randomized to receive either preoperative RIC (immediate or delayed) or no conditioning.
Additional analyses include continuous postoperative monitoring of microcirculation, histological and molecular assessment of tissue samples, and evaluation of circulating biomarkers associated with tissue protection.
The study aims to evaluate whether preoperative RIC improves postoperative flap perfusion, reduces ischemia-reperfusion- related tissue damage, and enhances clinical outcomes such as flap survival, wound healing, and need for revision surgery. Patients undergoing free flap procedures will be randomized to receive either preoperative RIC (immediate or delayed) or no conditioning.
Additional analyses include continuous postoperative monitoring of microcirculation, histological and molecular assessment of tissue samples, and evaluation of circulating biomarkers associated with tissue protection.
Detailed Description:
Background Free flap reconstruction represents the gold standard for complex soft tissue defects arising from tumor resection, trauma, or chronic wounds. Despite refinements in microsurgical technique and perioperative management, flap-related complications, including partial necrosis, wound healing disorders, and total flap loss, continue to occur at clinically meaningful rates. The underlying pathophysiology involves obligatory ischemia during flap harvest and transfer, followed by reperfusion upon anastomosis completion. This ischemia-reperfusion (I/R) sequence triggers a cascade of oxidative stress, endothelial dysfunction, inflammatory activation, and microcirculatory failure that can ultimately compromise tissue viability.
Current intraoperative strategies to mitigate I/R injury remain limited, and no pharmacological or mechanical intervention has been established as standard of care in this context.
Scientific Rationale for Remote Ischemic Conditioning Remote Ischemic Conditioning (RIC) exploits the endogenous capacity of biological tissue to develop tolerance to ischemic stress when exposed to brief, non-lethal cycles of ischemia and reperfusion at a site distant from the target organ. Originally described in cardiac surgery, RIC has since been investigated across a range of ischemia-sensitive tissues and clinical scenarios. Proposed mechanisms include neuronal and humoral signaling pathways that activate cytoprotective programs, such as upregulation of heat shock proteins, modulation of the RISK (Reperfusion Injury Salvage Kinase) pathway, suppression of mitochondrial permeability transition pore opening, and attenuation of neutrophil-mediated endothelial injury.
Preclinical models of pedicled and free flaps have demonstrated improved perfusion, reduced apoptosis, and enhanced flap survival following RIC. However, these findings have not yet been translated into a prospective randomized clinical trial in reconstructive microsurgery.
Timing of Conditioning: Study Design Rationale A key unresolved question concerns the optimal timing of RIC relative to surgery. Two biologically distinct windows of protection have been described: an immediate window (within approximately 1-2 hours of the conditioning stimulus, mediated largely by post-translational protein modifications) and a delayed window (emerging 12\*24 hours later, dependent on de novo protein synthesis and gene expression changes). To address this, the trial incorporates three parallel arms: a non-conditioned control group, an immediately preconditioned group (approximately 1 hour before surgery), and a delayed preconditioned group (12-24 hours preoperatively). This design enables direct comparison of both conditioning windows against each other and against standard care.
In cases where intraoperative findings necessitate unplanned revision surgery, a secondary randomization procedure is pre-specified to evaluate the potential benefit of RIC in the setting of threatened flap perfusion.
Intervention Protocol RIC is applied non-invasively to the upper arm using a standard pneumatic tourniquet. Each conditioning session consists of three alternating cycles of 10-minute ischemia (cuff inflated to approximately 250 mmHg, sufficient to occlude arterial inflow) and 10-minute reperfusion (cuff deflated), for a total session duration of 60 minutes. This protocol is consistent with those used in cardiovascular RIC trials and has a well-characterized safety profile.
Microcirculatory Monitoring Postoperative flap perfusion will be continuously assessed using a multimodal approach combining laser Doppler flowmetry and tissue spectrometry (O2C device or equivalent). These complementary techniques enable real-time, non-invasive quantification of microvascular flow, tissue oxygen saturation, and relative hemoglobin concentration. Measurements will be obtained at standardized time points throughout the first five postoperative days, allowing construction of perfusion trajectories and identification of early signs of compromised microcirculation.
Tissue and Biomarker Analyses Standardized biopsies will be obtained from clinically non-essential portions of the flap at defined intraoperative and early postoperative time points. Samples will undergo histological and immunohistochemical evaluation for markers of ischemic injury, cellular stress responses, inflammatory infiltration, and apoptosis. Parallel molecular analyses will characterize expression of proteins and signaling mediators implicated in I/R injury and cytoprotection.
Serial blood samples will be collected perioperatively to quantify circulating biomarkers, including but not limited to markers of oxidative damage, endothelial activation, and systemic inflammatory response. These analyses serve both to detect systemic correlates of local tissue protection and to identify candidate biomarkers for future use in monitoring RIC efficacy.
Clinical Outcome Assessment In addition to mechanistic endpoints, the trial will capture a comprehensive set of clinical outcomes through postoperative day 5 and beyond, including flap survival rate, incidence and severity of wound healing disorders, requirement for revision surgery or re-anastomosis, and total length of inpatient stay. Adverse events and protocol deviations will be systematically recorded.
Statistical Considerations Sample size estimation is based on the primary perfusion endpoint. Randomization will be performed centrally with stratification for relevant clinical variables. All primary analyses will follow the intention-to-treat principle; per-protocol analyses will be conducted as sensitivity analyses.
Significance If RIC is demonstrated to improve perfusion and reduce I/R injury in this setting, it would offer a compelling adjunct to reconstructive microsurgery: it is non-invasive, requires no specialized pharmacology, adds minimal procedural complexity, and is associated with a favorable safety profile in other surgical disciplines. The results of this trial are expected to inform evidence-based guidelines for perioperative conditioning in free flap surgery and to lay the groundwork for larger multicenter investigations.
Current intraoperative strategies to mitigate I/R injury remain limited, and no pharmacological or mechanical intervention has been established as standard of care in this context.
Scientific Rationale for Remote Ischemic Conditioning Remote Ischemic Conditioning (RIC) exploits the endogenous capacity of biological tissue to develop tolerance to ischemic stress when exposed to brief, non-lethal cycles of ischemia and reperfusion at a site distant from the target organ. Originally described in cardiac surgery, RIC has since been investigated across a range of ischemia-sensitive tissues and clinical scenarios. Proposed mechanisms include neuronal and humoral signaling pathways that activate cytoprotective programs, such as upregulation of heat shock proteins, modulation of the RISK (Reperfusion Injury Salvage Kinase) pathway, suppression of mitochondrial permeability transition pore opening, and attenuation of neutrophil-mediated endothelial injury.
Preclinical models of pedicled and free flaps have demonstrated improved perfusion, reduced apoptosis, and enhanced flap survival following RIC. However, these findings have not yet been translated into a prospective randomized clinical trial in reconstructive microsurgery.
Timing of Conditioning: Study Design Rationale A key unresolved question concerns the optimal timing of RIC relative to surgery. Two biologically distinct windows of protection have been described: an immediate window (within approximately 1-2 hours of the conditioning stimulus, mediated largely by post-translational protein modifications) and a delayed window (emerging 12\*24 hours later, dependent on de novo protein synthesis and gene expression changes). To address this, the trial incorporates three parallel arms: a non-conditioned control group, an immediately preconditioned group (approximately 1 hour before surgery), and a delayed preconditioned group (12-24 hours preoperatively). This design enables direct comparison of both conditioning windows against each other and against standard care.
In cases where intraoperative findings necessitate unplanned revision surgery, a secondary randomization procedure is pre-specified to evaluate the potential benefit of RIC in the setting of threatened flap perfusion.
Intervention Protocol RIC is applied non-invasively to the upper arm using a standard pneumatic tourniquet. Each conditioning session consists of three alternating cycles of 10-minute ischemia (cuff inflated to approximately 250 mmHg, sufficient to occlude arterial inflow) and 10-minute reperfusion (cuff deflated), for a total session duration of 60 minutes. This protocol is consistent with those used in cardiovascular RIC trials and has a well-characterized safety profile.
Microcirculatory Monitoring Postoperative flap perfusion will be continuously assessed using a multimodal approach combining laser Doppler flowmetry and tissue spectrometry (O2C device or equivalent). These complementary techniques enable real-time, non-invasive quantification of microvascular flow, tissue oxygen saturation, and relative hemoglobin concentration. Measurements will be obtained at standardized time points throughout the first five postoperative days, allowing construction of perfusion trajectories and identification of early signs of compromised microcirculation.
Tissue and Biomarker Analyses Standardized biopsies will be obtained from clinically non-essential portions of the flap at defined intraoperative and early postoperative time points. Samples will undergo histological and immunohistochemical evaluation for markers of ischemic injury, cellular stress responses, inflammatory infiltration, and apoptosis. Parallel molecular analyses will characterize expression of proteins and signaling mediators implicated in I/R injury and cytoprotection.
Serial blood samples will be collected perioperatively to quantify circulating biomarkers, including but not limited to markers of oxidative damage, endothelial activation, and systemic inflammatory response. These analyses serve both to detect systemic correlates of local tissue protection and to identify candidate biomarkers for future use in monitoring RIC efficacy.
Clinical Outcome Assessment In addition to mechanistic endpoints, the trial will capture a comprehensive set of clinical outcomes through postoperative day 5 and beyond, including flap survival rate, incidence and severity of wound healing disorders, requirement for revision surgery or re-anastomosis, and total length of inpatient stay. Adverse events and protocol deviations will be systematically recorded.
Statistical Considerations Sample size estimation is based on the primary perfusion endpoint. Randomization will be performed centrally with stratification for relevant clinical variables. All primary analyses will follow the intention-to-treat principle; per-protocol analyses will be conducted as sensitivity analyses.
Significance If RIC is demonstrated to improve perfusion and reduce I/R injury in this setting, it would offer a compelling adjunct to reconstructive microsurgery: it is non-invasive, requires no specialized pharmacology, adds minimal procedural complexity, and is associated with a favorable safety profile in other surgical disciplines. The results of this trial are expected to inform evidence-based guidelines for perioperative conditioning in free flap surgery and to lay the groundwork for larger multicenter investigations.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: